Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access

DALLAS and NEW YORK, March 23, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has named Anthony Mottola as its Vice President of Managed Care and Market Access.  A 16-year industry veteran, Mottola brings to Access an extensive pharmaceutical industry knowledge and experience in specialty pharmacy, healthcare services and reimbursement solutions.  Anthony will lead the overall management of reimbursement and market access for MuGard within Access Pharmaceuticals.

Prior to joining Access, Anthony served as VP of Trade for BioScrip, where he developed customized distribution strategies, patient access and reimbursement programs to support the successful launch of various products, including MuGard.  He was previously Associate Director National Accounts for Novartis, where he was responsible for the management and development of multiple national accounts, including Specialty Pharmacies, Reimbursement HUB Providers, Specialty distributors, GPO’s, Managed Care Plans such as Cigna, Humana, Wellpoint and Government Organizations.  Prior to Novartis, Anthony served in different capacities of sales management, mainly in the oncology area, at Pfizer, US Bioservices and Abbott Laboratories.

Read more »

Access Pharmaceuticals to Host Update Conference Call for Investors

Dallas, TX and New York, NY, March 01, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, will host a conference call on Wednesday, March 23rd to update investors on its ongoing commercial and development strategy. Management will discuss the progress made within each of Access’ programs, including an update on commercial launch activities and schedule for MuGard, the company’s oral mucositis supportive care product; its Cobalamin CobOral and CobaCyte programs, as well as the advancement of both its Thiarabine Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center, and ProLindac phase 2 combination trial in recurrent ovarian cancer.
Read more »